#$%^&*AU2018101584A420181129.pdf#####Abstract The invention relates to the field of medicine, in particular, it relates to the use of an antiplatelet thrombolysin in the preparation of a medicament for treating Thrombotic Thrombocytopenic Purpura (TTP).The main pathogenesis of TTP is von Willebrand factor cleaving enzyme, that is, ADAMTS13, is defective in innate expression or is inhibited by autoantibodies, resulting in the accumulation of von Willebrand factor (vWF) in the body, developing into multiple super large polymer , which mediates pathological platelet aggregation and thrombosis, and eventually leads to TTP. The antiplatelet thrombolysin of the invention can limit platelet adhesion and aggregation, restore platelets, red blood cell and hemoglobin levels, at the same time, reduce the level of lactate dehydrogenase, and effectively inhibits thrombocytopenia and schistocyte hemolytic anemia, so as to achieve the purpose of the treatment of TTP, which has a good prospect of clinical use.
